Esomeprazole potassium salt ((S)-Omeprazole potassium) |
| Catalog No.GC33575 |
La sal potÁsica de esomeprazol ((S)-Omeprazol potÁsico) ((S)-Omeprazol potÁsico) es un inhibidor de la bomba de protones potente y activo por vÍa oral y reduce la secreciÓn de Ácido mediante la inhibiciÓn de la ATPasa H+, K+- en las células parietales gÁstricas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 161796-84-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Esomeprazole potassium salt is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells.IC50 value:Target: proton pumpEsomeprazole potassium salt is a proton pump inhibitor and gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.
[1]. Thomas C Kupiec, Vasileios Aloumanis, Michel Ben, et al. Physical and Chemical Stability of Esomeprazole Sodium Solutions. Ann Pharmacother. September 2008 ,42 ( 9 ):1247-1251. [2]. Esomeprazole [3]. Sandstrom M, et al. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. Clin Ther. 2012 Aug;34(8):1828-38. [4]. Johnson TJ, Hedge DD. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *